Evidence map›Paper›PMID 31491926›Full record

ArticleCancers2019

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.

Martina Kirchner, Olaf Neumann, Anna-Lena Volckmar, Fabian Stögbauer, Michael Allgäuer, Daniel Kazdal, Jan Budczies, Eugen Rempel, Regine Brandt, Suranand Babu Talla and 9 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Guidelines for clinical practice ofJournal of the National Cancer Center · 2021
    Article
  15. Article
  16. Article
  17. Mutational landscape of primary and recurrent Ewing sarcoma.Contemporary oncology (Poznan, Poland) · 2021
    Article
  18. Article
  19. Article
  20. TRK Inhibitors in Non-Small Cell Lung Cancer.Current treatment options in oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Martina KirchnerInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-4426-2400
Olaf NeumannInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Anna-Lena VolckmarInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Fabian StögbauerInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Michael AllgäuerInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-4518-7887
Daniel KazdalInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Jan BudcziesInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Eugen RempelInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Regine BrandtInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Suranand Babu TallaInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Moritz von WinterfeldInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Jonas LeichsenringInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Tilmann BochtlerClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Alwin KrämerClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Christoph SpringfeldDepartment of Internal Medicine VI, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Peter SchirmacherInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Roland PenzelInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Volker EndrisInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0003-2550-3563
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany. albrecht.stenzinger@med.uni-heidelberg.de.
Heidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncogenic gene fusions are important drivers in many cancer types, including carcinomas, with diagnostic and therapeutic implications. Hence, sensitive and rapid methods for parallel profiling in formalin-fixed and paraffin-embedded (FFPE) specimens are needed. In this study we analyzed gene fusions in a cohort of 517 cases where standard treatment options were exhausted. To this end the Archer

Indexed as

carcinomagene fusionNGSsolid tumortargeted therapy

Identifiers

PMID31491926
PMCPMC6769558
OpenAlexW2971625494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.